Abstract
Introduction/BackgroundDespite impressive progression free survival (PFS) results from PARP inhibitors (PARPi) in ovarian cancer (OC), concerns about their effect on post-progression treatment outcomes have recently arisen, particularly in the relapsed...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
